Pharvaris (PHVS) Enterprise Value (2019 - 2026)
Pharvaris' (PHVS) quarterly Enterprise Value came in at -$289.1 million in Q1 2026, down 16.22% YoY from -$345.1 million in Q1 2025, and up 14.84% on a QoQ basis from -$339.5 million in Q4 2025.
Pharvaris (PHVS) Enterprise Value (2019 - 2026) Analysis & Trends
Pharvaris (PHVS) has 8 years of Enterprise Value data on file, last reported at -$289.1 million in Q1 2026.
- Quarterly Enterprise Value fell 16.22% year-over-year to -$289.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$289.1 million (down 16.22% YoY) and the FY2025 annual result came in at -$329.5 million, down 8.46% from the prior year.
- Enterprise Value rose to -$289.1 million in Q1 2026, from -$339.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$145.1 million in Q1 2023 to a low of -$420.9 million in Q4 2023.
- A 5-year average of -$272.1 million and a median of -$248.8 million in 2025 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value plunged 175.79% — and 2025, when it surged 38.94%.
- Tracing PHVS's Enterprise Value over 5 years: stood at -$165.1 million in 2022, then tumbled by 154.94% to -$420.9 million in 2023, then grew by 28.73% to -$300.0 million in 2024, then retreated by 13.18% to -$339.5 million in 2025, then increased by 14.84% to -$289.1 million in 2026.
- The last three Enterprise Value figures came in at -$289.1 million (Q1 2026), -$339.5 million (Q4 2025), and -$385.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Pharvaris | 2.29 Bn | 1.92 Bn | - | -369.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -369.96 Mn |
| Mar 31, 2026 | -289.13 Mn |
| Dec 31, 2025 | -339.53 Mn |
| Sep 30, 2025 | -384.95 Mn |
| Jun 30, 2025 | -225.91 Mn |
| Mar 31, 2025 | -248.77 Mn |
| Dec 31, 2024 | -299.98 Mn |
| Sep 30, 2024 | -335.17 Mn |
| Jun 30, 2024 | -369.99 Mn |
| Mar 31, 2024 | -400.15 Mn |
| Dec 31, 2023 | -420.94 Mn |
| Sep 30, 2023 | -172.39 Mn |
| Jun 30, 2023 | -195.12 Mn |
| Mar 31, 2023 | -145.10 Mn |
| Dec 31, 2022 | -165.11 Mn |
| Sep 30, 2022 | -199.37 Mn |
| Jun 30, 2022 | -214.89 Mn |
| Mar 31, 2022 | -218.60 Mn |
| Dec 31, 2021 | -239.49 Mn |
| Sep 30, 2021 | -257.79 Mn |